

REGENERATIVE MEDICINES: BONE AND JOINT APPLICATIONS



PHM032D
May 2015

Kevin Gainer
Project Analyst

ISBN: 1-62296-090-4



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
OBJECTIVES AND GOALS OF STUDY	2
INTENDED AUDIENCE	3
STUDY SCOPE AND FORMAT	3
METHODOLOGY	4
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2014-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW AND OVERALL STATUS OF THE INDUSTRY	10
SCOPE OF REGENERATIVE MEDICINE MARKET	10
ESTIMATED NUMBER OF COMPANIES IN REGENERATIVE SECTOR	10
<i>TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR</i>	11
<i>TABLE 2 MOST PROMINENT COMPANIES IN THE REGENERATIVE MEDICINE BUSINESS</i>	12
SIZE OF ORTHOPEDIC SECTOR AND LEADING SUPPLIERS	13
<i>TABLE 3 REVENUES FOR TOP SUPPLIERS OF ORTHOPEDIC PRODUCTS AND MATERIALS, 2014 (\$ BILLIONS)</i>	13
HOW REGENERATIVE MEDICINE WORKS	14
TISSUES AND ORGANS ON DEMAND	15
ORGAN REPLACEMENT IS A \$100 BILLION PER YEAR BUSINESS	15
EXAMPLES OF IMPACT ON EXISTING CONDITIONS AND DISEASES	16
BARRIERS TO REGENERATIVE MEDICINE	16
<i>TABLE 4 NINE PRINCIPAL MARKET DRIVERS</i>	18
CURRENT R&D PRIORITIES	18
<i>TABLE 5 R & D FOCUSES FOR PRINCIPAL REGENERATIVE MEDICINE</i>	18
<i>TABLE 6 TWENTY-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS</i>	20
NATIONAL SCIENCE FOUNDATION PRIORITIES	20
<i>TABLE 7 NATIONAL SCIENCE FOUNDATION REGENERATIVE MEDICINE FUNDING PRIORITIES, APRIL 1, 2015 (\$)</i>	21
TOTAL OUTPUT OF THE SECTOR	21
REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS	22
POPULATION TRENDS	23
MARKET TIMING	23
OVERSEAS INITIATIVES	23
CHAPTER 4 PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE	25
HUMAN SUBSTANCES	26

TOPIC	PAGE NO.
CELLS AND TISSUES	26
TISSUE ENGINEERING	26
Importance of Scaffolding in Tissue Engineering	26
Plastic Scaffolding	27
Blood Vessel Scaffolding	28
Center for Integration of Medicine and Innovative Technology (CIMIT)	28
<i>TABLE 8 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008-2012</i>	28
Massachusetts General Hospital	29
Duke University Stem Cell and Regenerative Medicine Program	30
University of Iowa	30
EMBRYONIC STEM CELLS	31
Therapeutic Cloning	31
ADULT STEM CELLS: JUST AS GOOD AS EMBRYONIC STEM CELLS	31
Genzyme	32
University of Minnesota Stem Cell Institute	32
STEM CELL RESEARCH PATENTS AND EFFECT ON STEM CELL MARKETERS	33
Stem Cells via Indirect Lineage Conversion (ILC)	33
COMPANIES INVOLVED IN BONE AND JOINT STEM CELL-BASED THERAPEUTICS	34
<i>TABLE 9 COMPANIES INVOLVED IN BONE AND JOINT STEM CELL-BASED THERAPEUTICS</i>	35
SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS	35
NOVEL MATERIALS	36
Nanoneedles	36
GENE THERAPY	36
Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders	37
BIOREACTOR USE IN REGENERATIVE MEDICINE	38
<i>TABLE 10 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE</i>	38
THE IMPACT OF GENOMICS	38
CHAPTER 5 PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE	41
GENE- AND PROTEIN-BASED APPROACHES	41
ANTIBODIES	41
The Importance of Antibody Drugs	42
Advantages of Monoclonal Antibody Drugs	43
Antibodies and Osteoarthritis	43
Denosumab	45
GROWTH FACTORS	45
HOW BMPs FUNCTION	46
<i>TABLE 11 BONE MORPHOGENETIC PROTEINS</i>	47
Clinical Uses	47
Companies	48
CELLS AND TISSUES	49
TISSUE ENGINEERING	49
ARTIFICIAL SKIN	50

TOPIC	PAGE NO.
CARTILAGE	51
Other Approaches to Cartilage	52
haMPC Therapy for Knee Osteoarthritis	53
Biosynthetic Composites for Cartilage Repair	53
3D Tissue Printing of Cartilage	53
3D Tissue Printing of Bone	54
Histogenics	54
Columbia University Work	55
The Market for Tissue-Engineered Cartilage Products	55
<i>TABLE 12 U.S. MARKET FOR TISSUE-ENGINEERED AND CELL THERAPY-BASED CARTILAGE PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	55
OTHER PRODUCTS	56
CREATION OF ENTIRE ORGANS	56
EMBRYONIC STEM CELLS	57
NOVEL MATERIALS AND BIOMATERIALS	58
<i>TABLE 13 WORLD'S LARGEST IMPLANTABLE BIOMATERIALS COMPANIES</i>	59
CHAPTER 6 STEM CELL THERAPIES AND REGENERATIVE MEDICINE	62
STEM CELLS AS POTENTIAL REPLACEMENT CELLS	62
OVERALL MARKET AND PARTICIPANTS	63
STEM CELL MARKET RISKS	63
TECHNICAL IMPEDIMENTS	64
OVERVIEW OF FUNDING	64
<i>TABLE 14 FEDERAL FUNDING FOR STEM CELL RESEARCH, THROUGH 2013 (\$ MILLIONS)</i>	65
STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH	65
<i>TABLE 15 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH</i>	66
POTENTIAL APPLICATIONS: CURRENT STATUS	66
IN VIVO REPROGRAMMING	67
UMBILICAL CORD BLOOD STEM CELLS	67
Recent Research Developments	68
INDUCED PLURIPOTENT STEM CELLS	68
Recent Research Developments	68
Adult Multipotent Stem Cells	69
Embryonic Stem Cells	69
Adipose Stem Cells for Bone and Joint Applications	71
GERON AND THE FIRST HUMAN TRIALS	72
OTHER STEM CELL RESEARCH	74
STATUS OF OTHER CLINICAL TRIALS	74
STEM CELL THERAPY FOR ALS	75
STEM CELL THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY	76
STEM CELL THERAPY AND BONE MARROW TRANSPLANTS	77
CHAPTER 7 REGENERATIVE PRODUCTS TO TREAT BONE DISEASES	79
REGENERATIVE PRODUCTS TO TREAT BONE DISEASES	79
OSTEOBIOLOGICS	79
BONE GRAFTS	80
PRINCIPAL USES OF BONE GRAFTS	80

TOPIC	PAGE NO.
<i>TABLE 16 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL</i>	81
<i>TABLE 17 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2020 (NUMBER)</i>	82
<i>TABLE 18 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2020 (NUMBER)</i>	82
<i>TABLE 19 BONE GRAFT MATERIALS</i>	83
<i>TABLE 20 SUBSTITUTE BONE GRAFTS</i>	84
AUTOGRAFTS	84
BIOSEED GRAFTS	85
ALLOGRAFTS	86
Demineralized Bone Matrix Products	88
<i>TABLE 21 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX</i>	88
Allograft Suppliers	88
Accell	89
AlphaGRAFT	89
Allomatrix	89
Bioset, BioReady	89
Mozaik	89
Grafton DBM	90
DBX	90
DynaBlast and DynaGraft-D	90
Graftech	90
Grafton	90
Opteform	91
OrthoBlast II	91
AlphaGRAFT	91
Xenografts	91
Market for Allografts	91
<i>TABLE 22 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2020 (\$ MILLIONS)</i>	92
BONE REPLACEMENT AND REPAIR PRODUCTS	92
CELL-BASED BONE GRAFT SUBSTITUTES	92
Factor-based Bone Graft Substitutes	93
BONE MORPHOGENIC PROTEINS	94
InductOs	95
InFUSE Bone Graft	95
OP-1 Implant	96
CERAMIC-BASED BONE GRAFT SUBSTITUTES	96
Bioactive Glasses	97
Types of Ceramics	97
Alpha-BSM	98
BioActys	98
BioGran	98
Bio-Oss	99
BoneSource	99
Calcigen S	99
Collagraft Strip Bone Graft Matrix	99

TOPIC	PAGE NO.
Conduit TCP Granules	100
Exabone	100
Gamma-bsm	100
IsoTis Products	100
Mimix Bone Substitute Material	101
Norian SRS	101
OsteoGraf	101
OsteoMatrix	101
Osteoset	101
Osteostim Resorbable Bone Graft Substitute	102
PerioGlas	102
Pro Osteon Implant	102
Vitoss	102
POLYMER-BASED BONE GRAFT SUBSTITUTES	103
Cortoss	103
Healos	104
Immixon Extenders and Immixon CB	104
MARKET FOR BONE GRAFT PRODUCTS	105
<i>TABLE 23 GLOBAL MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	105
<i>TABLE 24 U.S. MARKET FOR BONE-REPLACEMENT AND GRAFTING PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	106
RESEARCH AND DEVELOPMENT OF OTHER REGENERATIVE MEDICINE PRODUCTS FOR BONE APPLICATIONS	106
BIOLOGIC/SYNTHETIC GRAFTS	106
CHRYSALIN	107
NEW SCAFFOLDING TECHNIQUES	108
Honeycomb Implants	108
Electrospun Fiber Multiwell Plates	108
BIOCELLULAR GRAFTS	108
CHAPTER 8 REGENERATIVE APPLICATIONS FOR BONES AND JOINTS	111
MATERIALS FOR BONE TISSUE REPAIR	111
<i>TABLE 25 EXAMPLES OF NANOSTRUCTURED BIOMATERIALS USEFUL IN BONE AND JOINT REGENERATION</i>	111
VANADIUM COMPOUNDS TO ACCELERATE BONE HEALING	112
BIONANOPARTICLES IN BONE HEALING	112
BIODEGRADABLE NANOSCALE FILAMENTS	113
SILK PROTEIN MICROFIBERS	114
INHERENT REGENERATION OF BONE	114
OVERALL SIZE OF BONE GRAFT BUSINESS	115
BONE GRAFT SUBSTITUTES	116
ALLOGRAFT TISSUE	117
OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES	118
HYDROGELS AND REGENERATION	118
UNIVERSITY OF ROCHESTER RESEARCH ON HYDROGELS	119
HYDROGEL SCAFFOLDING	120
HYDROGEL PATENTS	120

TOPIC	PAGE NO.
Bone Implant Materials Comprising Cross-Linked Bioactive Hydrogel Matrices	121
Abstract	121
Hydrogel Bone Void Filler	121
Abstract	121
Amphiphilic Peptides and Hydrogel Matrices Thereof for Bone Repair	121
Abstract	122
Hydrogel Bioscaffold and Coating for Bone and Tooth Repair	122
Abstract	122
Antimicrobial Nanostructured Hydrogel Web Containing Silver	122
Abstract	122
Injectable Peptide Hydrogel That Kills Methicillin-Resistant Staphylococcus Aureus	123
Abstract	123
Method to Repair a Damaged Intervertebral Disc Through the Use of a Bioadhesive, Thermogelling Hydrogel	123
Abstract	123
Hydrogel Compositions	124
Abstract	124
Self-Assembling Protein Hydrogel With Bio-Active Protein	124
Abstract	124
Superporous Hydrogel with Cells Encapsulated Therein and Method for Producing the Same	124
Abstract	125
Hydrogel Particles	125
Abstract	125
Composition and Method for Self-Assembly and Mineralization of Peptide Amphiphiles	125
Abstract	125
Chondroitinase ABC I Polynucleotides	126
Abstract	126
Transdiscal Administration of Cycline Compounds	126
Abstract	127
Composition and Method for Preparing Biocompatible Surfaces	127
Abstract	127
Spinal Mobility Preservation Apparatus Having an Expandable Membrane	127
Abstract	127
MAJOR DISEASES AND CONDITIONS AFFECTING BONES	128
OSTEOPOROSIS	128
Currently Available Products to Treat Osteoporosis	129
Bisphosphonates	130
Fosamax	130
Boniva	131
New Approaches	131
Sclerostin Antibody	131
Romosozumab	131
Probiotics	132
Stem Cell Treatments	132

TOPIC	PAGE NO.
<i>TABLE 26 DRUGS USED TO TREAT OSTEOPOROSIS</i>	133
Hormones	133
Evista	134
Forteo	134
Miacalcin	136
STERIODS AND OSTEOPOROSIS	136
Glucocorticoids	136
MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS	137
<i>TABLE 27 GLOBAL MARKET FOR DRUGS TO TREAT OSTEOPOROSIS BY CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>	138
PAGET'S DISEASE	138
DRUGS CURRENTLY AVAILABLE TO TREAT PAGET'S DISEASE	138
Actonel	139
Aredia	139
Skelid	139
Zometa	139
MARKET FOR PRODUCTS TO TREAT PAGET'S DISEASE	139
<i>TABLE 28 GLOBAL MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2020 (\$ MILLIONS)</i>	140
INJURIES AND DEGENERATIVE CONDITIONS	140
HIP FRACTURES	141
<i>TABLE 29 GLOBAL HIP FRACTURE VOLUMES, THROUGH 2020 (NUMBER)</i>	141
<i>TABLE 30 U.S. HIP FRACTURE VOLUMES, THROUGH 2020 (NUMBER/%)</i>	142
TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS	142
<i>TABLE 31 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS BY CATEGORY, 2014 (%)</i>	142
<i>TABLE 32 U.S. MARKET SHARES FOR RECONSTRUCTIVE DEVICES BY CATEGORY, 2014 (%)</i>	143
MARKET LEADERS	143
JOINT-REPLACEMENT SURGERY	143
<i>TABLE 33 NUMBER OF U.S. HIP REPLACEMENT PROCEDURE VOLUMES, THROUGH 2020</i>	143
<i>TABLE 34 NUMBER OF HIP REPLACEMENT PROCEDURES IN SIX MAJOR STATES, 2001</i>	144
<i>TABLE 35 GLOBAL MARKET FOR HIP REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	144
<i>TABLE 36 U.S. MARKET FOR HIP REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	144
KNEE REPLACEMENTS	145
VENDORS	145
<i>TABLE 37 GLOBAL KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2020 (NUMBER)</i>	145
<i>TABLE 38 U.S. KNEE REPLACEMENT PROCEDURES, THROUGH 2020 (NUMBER)</i>	146
<i>TABLE 39 GLOBAL MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	146
<i>TABLE 40 U.S. MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	146
<i>TABLE 41 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	147
NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS	147
IMAGING MARKETS AND REGENERATIVE THERAPIES	148

TOPIC	PAGE NO.
CHAPTER 9 ELECTRICAL BONE GROWTH STIMULATOR MARKET	151
OVERVIEW	151
SCIENTIFIC BASIS	152
ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING	153
MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS	153
BIOMET	153
ORTHOFIX	155
DJO INC.	155
SMITH & NEPHEW (BIOVENTUS)	156
MARKET SIZE	156
<i>TABLE 42 GLOBAL MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	157
<i>TABLE 43 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	157
R&D - FUTURE PRODUCT POSSIBILITIES	157
CHAPTER 10 ORTHOPEDICS - FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT	160
SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS	160
<i>TABLE 44 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, 2008-2015</i>	161
CHAPTER 11 MARKET FOR TISSUE ENGINEERING PRODUCTS	181
COMPANY INVOLVEMENT	181
TISSUE ENGINEERING AND CELL THERAPY	181
RESEARCH INITIATIVES	182
NATIONAL INSTITUTES OF HEALTH (NIH)	184
DREXEL UNIVERSITY	185
BIO2 TECHNOLOGIES INC.	185
YESHIVA UNIVERSITY	186
CHAPTER 12 REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY	188
OVERVIEW	188
INDICATIONS AND HISTORY	188
CHARACTERISTICS AND MATERIALS	189
BARRIER MEMBRANES	189
Nonresorbable	189
Resorbable	189
COLLAGEN RESORBABLE MEMBRANES	190
SYNTHETIC RESORBABLE MEMBRANES	190
BIOENGINEERED HYBRID TEETH FROM AUTOLOGOUS GUM CELLS	190
STEM CELL STUDY RAISES HOPE FOR BONE REPAIR PASTES	191
DENTAL REGENERATIVE PRODUCT VENDORS	192
GEISTLICH PHARMA NORTH AMERICA INC.	192
ZIMMER	192
ORGANOGENESIS INC.	192
MATRICEL GMBH	193
COLLAGEN MATRIX INC.	193

TOPIC	PAGE NO.
CURASAN AG	193
CHAPTER 13 SKIN TECHNOLOGIES	195
<i>TABLE 45 EXAMPLES OF FDA APPROVED HUMAN SKIN SUBSTITUTES</i>	195
<i>TABLE 46 GLOBAL MARKET FOR ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)</i>	197
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS	197
SOLUBLE SYSTEMS	198
INVESTIGATIONAL SKIN AND SOFT TISSUE SUBSTITUTES	198
<i>TABLE 47 INVESTIGATIONAL SKIN AND SOFT TISSUE SUBSTITUTES, MARCH 2015</i>	198
CHAPTER 14 NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE	201
OVERVIEW	201
NEURODEGENERATIVE DISEASES	201
BEST PROSPECTS FOR STEM CELLS IN THIS MARKET	201
STROKE	201
MULTIPLE SCLEROSIS	202
ALZHEIMER'S	202
CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE SYMPTOMS	203
SPINAL CORD INJURY, NEURODEGENERATIVE DISEASES AND REGENERATIVE POTENTIAL	204
UNIVERSITY OF SOUTHERN CALIFORNIA (USC)	205
CHAPTER 15 REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE	207
OVERVIEW	207
ACTIVE COMPANIES	207
Aastrom	207
Amorcyte	207
Athersys Inc.	208
Capricor	208
Cytomedix	208
Cytori Therapeutics	208
Juventas Therapeutics	208
Mesoblast	208
VetriNova	209
GENETIC BASIS FOR REGENERATING CELLS AFTER HEART ATTACK	209
STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE	209
PARTICULAR R&D PRIORITIES	210
STEM CELLS AND BIOLOGICAL PACEMAKERS	212
HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS	212
OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART	213
CHAPTER 16 REGENERATIVE MEDICINE AND DIABETES	215
BACKGROUND	215
POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE	215
CLINICAL TRIALS	216
SERNOVA CORP	217

TOPIC	PAGE NO.
ATHERSYS INC.	217
MESOBLAST	217
VIACYTE	218
CHAPTER 17 FDA-APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE	220
CURRENT STATUS OF THE REGENERATIVE MEDICINE BUSINESS	220
REGULATORY AND LEGAL ENVIRONMENT	220
STATUS OF RESEARCH AND CLINICAL TRIALS	222
ANALYSIS OF CLINICAL TRIALS	223
<i>TABLE 48 REGENERATIVE MEDICINE CLINICAL TRIALS BY CATEGORY (NUMBER/%)</i>	224
<i>TABLE 49 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE, STATUS, CONDITIONS AND SPONSOR, MARCH 30, 2015</i>	224
CHAPTER 18 OVERSEAS ACTIVITIES	233
DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE COMPANIES	233
JAPAN	233
Japan's Regenerative Therapies Market Prospects	234
<i>TABLE 50 JAPAN'S MARKET FOR REGENERATIVE AND TISSUE ENGINEERING, 2009 AND 2020</i>	234
EUROPE	235
REMEDIC	235
Nanobiocom	236
Regenerating Bone Defects using New Biomedical Engineering Approaches - (REBORNE)	236
Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis - (GAMBA)	237
BIRAX	237
AUSTRALIA AND CHINA	237
CHAPTER 19 PATENT ANALYSIS	240
ANALYSIS	240
TISSUE ENGINEERING PATENTS	240
<i>TABLE 51 TOP PATENT ASSIGNEES IN THE TISSUE ENGINEERING FIELD</i>	241
GEOGRAPHIC DISTRIBUTION	241
<i>TABLE 52 GLOBAL DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED BY COUNTRY, 1985-2012 (%)</i>	242
RECENT PATENTS	242
METHOD FOR OBTAINING PANCREATIC PROGENITOR CELL USING NEPH3	242
Abstract	242
SPONTANEOUSLY IMMORTALIZED MULTIPONENT MESENCHYMAL CELL-LINE DERIVED FROM MOUSE SUBCUTANEOUS ADIPOSE TISSUE: TOOL FOR REGENERATIVE MEDICINE AND BIOACTIVE MOLECULES AND/OR DRUGS SCREENING	243
Abstract	243
METHODS OF MANUFACTURING BIOACTIVE GELS FROM EXTRACELLULAR MATRIX MATERIAL	243
Abstract	243
ALIMENTARY PROTEIN-BASED SCAFFOLDS (APS) FOR WOUND HEALING, REGENERATIVE MEDICINE AND DRUG DISCOVERY	244

TOPIC	PAGE NO.
Abstract	244
POLYMER CARRIER	244
Abstract	244
HERBAL COMPOSITION FOR THE TREATMENT OF WOUND HEALING, A REGENERATIVE MEDICINE	244
Abstract	244
MAGNETIC CELL AND METHOD OF USING THE SAME	245
Abstract	245
THREE-DIMENSIONAL BIOPRINTING OF BIOSYNTHETIC CELLULOSE (BC) IMPLANTS AND SCAFFOLDS FOR TISSUE ENGINEERING	245
Abstract	245
BIOMATERIAL BASED ON WHARTON'S JELLY FROM THE HUMAN UMBILICAL CORD	246
Abstract	246
NONWOVEN FABRIC AND PROCESS FOR PRODUCING THE SAME	246
Abstract	246
THERAPEUTIC APPLICATIONS OF P53 ISOFORMS IN REGENERATIVE MEDICINE, AGING AND CANCER	247
Abstract	247
DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES OF LONG NON-CODING RNAs FOR CANCER AND REGENERATIVE MEDICINE	247
Abstract	247
NANO/MACROPOROUS BONE TISSUE SCAFFOLDS FOR REGENERATIVE MEDICINE	248
Abstract	248
GUIDED DELIVERY OF CELL-, PARTICLE- AND DRUG-BASED THERAPIES	248
Abstract	248
TRANSGENIC NONHUMAN ANIMAL AND METHODS FOR STEM CELL ENGRAFTMENT	249
Abstract	249
METHODS FOR MODULATING THE PROLIFERATION AND DIFFERENTIATION POTENTIAL OF STEM CELLS AND PROGENITOR CELLS	249
Abstract	249
BIOPOLYMER PRODUCED BY FERMENTING THE EXTRACT OF SOYBEAN WITH FOLIC ACID AND A COMPOSITION CONTAINING THEREOF	249
Abstract	250
SUBPOPULATIONS OF BONE MARROW-DERIVED ADHERENT STEM CELLS AND METHODS OF USE THEREFOR	250
Abstract	250
METHOD FOR PREPARING BIOLOGICAL SCAFFOLD MATERIAL	250
Abstract	251
COMPOSITION FOR REGENERATIVE TREATMENT OF CARTILAGE DISEASE	251
Abstract	251
REGULATION OF STEM CELL GENE PRODUCTION WITH SPECIFIC AND SELECTIVE ELECTRIC AND ELECTROMAGNETIC FIELDS	251
Abstract	251
COMPOSITIONS AND METHODS FOR BONE FORMATION AND REMODELING	252
Abstract	252
NEURAL CELL POPULATIONS FROM PRIMATE PLURIPOTENT STEM CELLS	252
Abstract	252

TOPIC	PAGE NO.
OSTEOINDUCTIVE BONE MATERIAL	253
Abstract	253
GENES WITH ES CELL-SPECIFIC EXPRESSION	253
Abstract	253
USE OF TGF BETA SUPERFAMILY ANTAGONISTS AND NEUROTROPHINS TO MAKE NEURONS FROM EMBRYONIC STEM CELLS	254
Abstract	254
HYDROXYPHENYL CROSS-LINKED MACROMOLECULAR NETWORK AND APPLICATIONS THEREOF	254
Abstract	254
MAGNETIC CELL AND METHOD OF USING THE SAME	255
Abstract	255
DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS	255
Abstract	255
ISOLATION AND PRESERVATION OF FETAL HEMATOPOIETIC AND MESENCYMAL SYSTEM CELLS FROM NONCONTROVERSIAL MATERIALS AND/OR TISSUES RESULTING FROM MISCARRIAGES AND METHODS OF THERAPEUTIC USE	256
Abstract	256
USE OF TGF BETA SUPERFAMILY ANTAGONISTS TO MAKE DOPAMINERGIC NEURONS FROM EMBRYONIC STEM CELLS	256
Abstract	256
DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS	257
Abstract	257
METHOD FOR PREPARING NOVEL TRANSCRIPTION FACTORS AND USE	257
Abstract	257
ENDODERM CELLS FROM HUMAN EMBRYONIC STEM CELLS	257
Abstract	258
GENES WITH ES CELL-SPECIFIC EXPRESSION	258
Abstract	258
MARKER SYSTEM FOR PREPARING AND CHARACTERIZING HIGH-QUALITY HUMAN EMBRYONIC STEM CELLS	258
Abstract	258
CHAPTER 20 COMPANY PROFILES	261
<i>TABLE 53 PUBLICLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, MARCH 6, 2015 (\$/\$ MILLIONS)</i>	261
<i>TABLE 54 COMPANIES ESTIMATED SALES ATTRIBUTABLE TO REGENERATIVE THERAPIES (BONE AND JOINT), 2012 (\$ MILLIONS)</i>	262
ACELITY	262
AESCULAP INC.	263
ALPHATEC SPINE INC.	263
ANIKA THERAPEUTICS INC.	264
APERION BIOLOGICS INC.	264
ARTERIOCYTE MEDICAL SYSTEMS INC.	265
ARTHREX INC.	265
ARTHROCARE CORP.	265
AUDAX MEDICAL INC.	266

TOPIC	PAGE NO.
BAXTER	266
BERKELEY ADVANCED BIOMATERIALS INC.	267
BIOMATLANTE	267
BIOMET INC.	268
BIOMIMETIC THERAPEUTICS INC.	268
BIOSURFACE ENGINEERING TECHNOLOGIES (BIOSET)	269
BIOTIME INC.	270
BIOTISSUE TECHNOLOGIES GMBH	271
BONALIVE BIOMATERIALS LTD	271
BONE SOLUTIONS INC.	272
CAM BIOCERAMICS B.V.	272
CAPSTONE THERAPEUTICS	272
CELLING BIOSCIENCES LLC	273
CERAPEDICS INC.	273
CESCA THERAPEUTICS	274
CITAGENIX INC.	275
CO.DON AG	276
COLLPLANT LTD.	276
CONMED CORP.	277
CRYOLIFE INC.	277
CURASAN AG	278
CURIS	279
CYTORI THERAPEUTICS INC.	279
DELENEX THERAPEUTICS AG	280
DEPUY ORTHOPAEDICS INC. (UNIT OF THE DEPUY COMPANIES)	280
DISCGENICS	281
DJO SURGICAL	281
ETEX CORP.	282
EXABONE GMBH	282
EXACTECH INC.	283
FATE THERAPEUTICS INC.	284
GARNET BIOTHERAPEUTICS	284
GEISTLICH PHARMA AG	284
GERON CORP.	285
GRAFTYS	286
HARVARD BIOSCIENCE	286
HISTOGEN	286
INTEGRA LIFESCIENCES HOLDING CORP.	287
INTELLICELL BIOSCIENCES INC.	288
INTERNATIONAL STEM CELL CORP.	289
INTERPORE CROSS INTERNATIONAL	290
ISTO TECHNOLOGIES INC.	291
K2M INC.	291
KENSEY NASH CORP.	291
KUROS BIOSURGERY AG	292
MCEWEN CENTRE FOR REGENERATIVE MEDICINE	293
MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE	294

TOPIC	PAGE NO.
MEDTRONIC INC.	294
MESOBLAST LTD	295
MIMEDX GROUP INC.	296
NATIONAL CENTER FOR REGENERATIVE MEDICINE	296
NATIONAL TISSUE ENGINEERING CENTER (NTEC)	297
NEURALSTEM INC.	298
NOVABONE PRODUCTS LLC	299
NOVARTIS CORP.	299
NUO THERAPEUTICS	300
NUVASIVE	300
OCATA THERAPEUTICS INC.	301
OLYMPUS BIOTECH CORP.	301
OPEXA THERAPEUTICS INC.	302
ORGANOGENESIS INC.	302
ORTHOFIX INTERNATIONAL N.V.	303
ORTHOPEUTICS L.P.	303
OSIRIS THERAPEUTICS INC.	304
OSTEOGENICS BIOMEDICAL INC.	304
PARCELL LABORATORIES	305
PFIZER INC.	305
PLURISTEM THERAPEUTICS	305
PROMOCELL GMBH	306
REGENECURE LTD.	306
REGENTIS BIOMATERIALS LTD.	307
RENEURON	307
REPLACEMENT THERAPY MATERIALS (R.T. MAT)	308
REPLIGEN CORP.	308
ROSLIN CELLAB	309
RTI SURGICAL INC.	309
SANOFI BIOSURGERY	310
SCIL TECHNOLOGY GMBH	311
SHIRE REGENERATIVE MEDICINE	311
SIGMA-ALDRICH CORP.	312
SMITH & NEPHEW	312
STEMCELLS INC.	313
STRAUMANN USA LLC	313
STRYKER CORP.	314
SURGICAL SPECIALTIES, INC.	314
SYNTHES INC.	315
TEKNIMED	315
TEPHA INC.	316
TETEC TISSUE ENGINEERING TECHNOLOGIES AG	316
TIGENIX N.V.	317
UCB S.A. (HEADQUARTERS)	317
VERICEL CORP.	318
VIACYTE INC.	318
WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE	319

TOPIC	PAGE NO.
WRIGHT MEDICAL GROUP INC.	320
ZIMMER HOLDINGS INC.	321
OTHER ORGANIZATIONS INVOLVED IN REGENERATIVE MEDICINE R&D	322
ACADEMIC INSTITUTIONS	322
U.S. GOVERNMENT	323
OTHER SOCIETIES AND ORGANIZATIONS	323
CHAPTER 21 GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS	325

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR	11
TABLE 2 MOST PROMINENT COMPANIES IN THE REGENERATIVE MEDICINE BUSINESS	12
TABLE 3 REVENUES FOR TOP SUPPLIERS OF ORTHOPEDIC PRODUCTS AND MATERIALS, 2014 (\$ BILLIONS)	13
TABLE 4 NINE PRINCIPAL MARKET DRIVERS	18
TABLE 5 R & D FOCUSES FOR PRINCIPAL REGENERATIVE MEDICINE	18
TABLE 6 TWENTY-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS	20
TABLE 7 NATIONAL SCIENCE FOUNDATION REGENERATIVE MEDICINE FUNDING PRIORITIES, APRIL 1, 2015 (\$)	21
TABLE 8 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008-2012	28
TABLE 9 COMPANIES INVOLVED IN BONE AND JOINT STEM CELL-BASED THERAPEUTICS	35
TABLE 10 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE	38
TABLE 11 BONE MORPHOGENETIC PROTEINS	47
TABLE 12 U.S. MARKET FOR TISSUE-ENGINEERED AND CELL THERAPY-BASED CARTILAGE PRODUCTS, THROUGH 2020 (\$ MILLIONS)	55
TABLE 13 WORLD'S LARGEST IMPLANTABLE BIOMATERIALS COMPANIES	59
TABLE 14 FEDERAL FUNDING FOR STEM CELL RESEARCH, THROUGH 2013 (\$ MILLIONS)	65
TABLE 15 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH	66
TABLE 16 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL	81
TABLE 17 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2020 (NUMBER)	82
TABLE 18 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2020 (NUMBER)	82
TABLE 19 BONE GRAFT MATERIALS	83
TABLE 20 SUBSTITUTE BONE GRAFTS	84
TABLE 21 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX	88
TABLE 22 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2020 (\$ MILLIONS)	92
TABLE 23 GLOBAL MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2020 (\$ MILLIONS)	105
TABLE 24 U.S. MARKET FOR BONE-REPLACEMENT AND GRAFTING PRODUCTS, THROUGH 2020 (\$ MILLIONS)	106
TABLE 25 EXAMPLES OF NANOSTRUCTURED BIOMATERIALS USEFUL IN BONE AND JOINT REGENERATION	111
TABLE 26 DRUGS USED TO TREAT OSTEOPOROSIS	133
TABLE 27 GLOBAL MARKET FOR DRUGS TO TREAT OSTEOPOROSIS BY CATEGORY, THROUGH 2020 (\$ MILLIONS)	138
TABLE 28 GLOBAL MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2020 (\$ MILLIONS)	140
TABLE 29 GLOBAL HIP FRACTURE VOLUMES, THROUGH 2020 (NUMBER)	141
TABLE 30 U.S. HIP FRACTURE VOLUMES, THROUGH 2020 (NUMBER/%)	142

TABLE HEADING	PAGE NO.
TABLE 31 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS BY CATEGORY, 2014 (%)	142
TABLE 32 U.S. MARKET SHARES FOR RECONSTRUCTIVE DEVICES BY CATEGORY, 2014 (%)	143
TABLE 33 NUMBER OF U.S. HIP REPLACEMENT PROCEDURE VOLUMES, THROUGH 2020	143
TABLE 34 NUMBER OF HIP REPLACEMENT PROCEDURES IN SIX MAJOR STATES, 2001	144
TABLE 35 GLOBAL MARKET FOR HIP REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	144
TABLE 36 U.S. MARKET FOR HIP REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	144
TABLE 37 GLOBAL KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2020 (NUMBER)	145
TABLE 38 U.S. KNEE REPLACEMENT PROCEDURES, THROUGH 2020 (NUMBER)	146
TABLE 39 GLOBAL MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	146
TABLE 40 U.S. MARKET FOR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	146
TABLE 41 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	147
TABLE 42 GLOBAL MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	157
TABLE 43 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	157
TABLE 44 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, 2008-2015	161
TABLE 45 EXAMPLES OF FDA APPROVED HUMAN SKIN SUBSTITUTES	195
TABLE 46 GLOBAL MARKET FOR ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2020 (\$ MILLIONS)	197
TABLE 47 INVESTIGATIONAL SKIN AND SOFT TISSUE SUBSTITUTES, MARCH 2015	198
TABLE 48 REGENERATIVE MEDICINE CLINICAL TRIALS BY CATEGORY (NUMBER/%)	224
TABLE 49 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE, STATUS, CONDITIONS AND SPONSOR, MARCH 30, 2015	224
TABLE 50 JAPAN'S MARKET FOR REGENERATIVE AND TISSUE ENGINEERING, 2009 AND 2020	234
TABLE 51 TOP PATENT ASSIGNEES IN THE TISSUE ENGINEERING FIELD	241
TABLE 52 GLOBAL DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED BY COUNTRY, 1985-2012 (%)	242
TABLE 53 PUBLICLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, MARCH 6, 2015 (\$/\$ MILLIONS)	261
TABLE 54 COMPANIES ESTIMATED SALES ATTRIBUTABLE TO REGENERATIVE THERAPIES (BONE AND JOINT), 2012 (\$ MILLIONS)	262

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2014-2020 (\$ MILLIONS)	8